ブラウザの設定でJava Scriptの使用を有効にしてご利用ください。
出典:Wikipedia
出典:『Wikipedia』 (2011/07/01 04:13 UTC 版)
Pasireotide (SOM230) is an orphan drug currently in phase III studies for the treatment of Morbus Cushing. It was developed by Novartis. Pasireotid is a somatostatin analogue, which has a 40fold increased affinity to somatostatin receptor 5 than other somatostatin analogues.
Pasireotide